abstract |
The present invention relates to a hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof. It further relates to a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug, its use as medicament for the treatment of a IL-1 mediated disease, methods of application of such hydrogel-linked IL-1ra prodrugs or pharmaceutical compositions, methods of treatment, and containers comprising the hydrogel-linked IL-1ra prodrugs or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof. |